Literature DB >> 21197574

Enhancement of antibody production by the addition of Coenzyme-Q(10).

Yoshinobu Konno1, Motoi Aoki, Masakazu Takagishi, Naoto Sakai, Masamichi Koike, Kaori Wakamatsu, Shinji Hosoi.   

Abstract

Recently, there has been a growing demand for therapeutic monoclonal antibodies (MAbs) on the global market. Because therapeutic MAbs are more expensive than low-molecular-weight drugs, there have been strong demands to lower their production costs. Therefore, efficient methods to minimize the cost of goods are currently active areas of research. We have screened several enhancers of specific MAb production rate (SPR) using a YB2/0 cell line and found that coenzyme-Q(10) (CoQ(10)) is a promising enhancer candidate. CoQ(10) is well known as a strong antioxidant in the respiratory chain and is used for healthcare and other applications. Because CoQ(10) is negligibly water soluble, most studies are limited by low concentrations. We added CoQ(10) to a culture medium as dispersed nanoparticles at several concentrations (Q-Media) and conducted a fed-batch culture. Although the Q-Media had no effect on cumulative viable cell density, it enhanced SPR by 29%. In addition, the Q-Media had no effect on the binding or cytotoxic activity of MAbs. Q-Media also enhanced SPR with CHO and NS0 cell lines by 30%. These observations suggest that CoQ(10) serves as a powerful aid in the production of MAbs by enhancing SPR without changing the characteristics of cell growth, or adversely affecting the quality or biological activity of MAbs.

Entities:  

Year:  2011        PMID: 21197574      PMCID: PMC3080474          DOI: 10.1007/s10616-010-9330-9

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  50 in total

Review 1.  Economic aspects of commercial manufacture of biopharmaceuticals.

Authors:  Rolf G Werner
Journal:  J Biotechnol       Date:  2004-09-30       Impact factor: 3.307

2.  [The antioxidant protection of the heart by coenzyme Q10 in stable stenocardia of effort].

Authors:  A Kh Kogan; A L Syrkin; S V Drinitsina; I V Kokanova
Journal:  Patol Fiziol Eksp Ter       Date:  1999 Oct-Dec

Review 3.  Production of recombinant protein therapeutics in cultivated mammalian cells.

Authors:  Florian M Wurm
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

4.  Biopharmaceutical benchmarks 2006.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2006-07       Impact factor: 54.908

5.  Comparative transcriptional analysis of mouse hybridoma and recombinant Chinese hamster ovary cells undergoing butyrate treatment.

Authors:  Marcela De Leon Gatti; Katie F Wlaschin; Peter Morin Nissom; Miranda Yap; Wei-Shou Hu
Journal:  J Biosci Bioeng       Date:  2007-01       Impact factor: 2.894

6.  Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction.

Authors:  R B Singh; G S Wander; A Rastogi; P K Shukla; A Mittal; J P Sharma; S K Mehrotra; R Kapoor; R K Chopra
Journal:  Cardiovasc Drugs Ther       Date:  1998-09       Impact factor: 3.727

7.  Enhanced antibody production following intermediate addition based on flux analysis in mammalian cell continuous culture.

Authors:  Takeshi Omasa; Keisuke Furuichi; Tomoya Iemura; Yoshio Katakura; Michimasa Kishimoto; Ken-Ichi Suga
Journal:  Bioprocess Biosyst Eng       Date:  2009-07-10       Impact factor: 3.210

8.  Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production.

Authors:  R R Balcarcel; G Stephanopoulos
Journal:  Biotechnol Bioeng       Date:  2001       Impact factor: 4.530

Review 9.  Coenzyme Q10 in neuromuscular and neurodegenerative disorders.

Authors:  M Mancuso; D Orsucci; L Volpi; V Calsolaro; G Siciliano
Journal:  Curr Drug Targets       Date:  2010-01       Impact factor: 3.465

10.  Enhanced antibody production of human-human hybridomas by retinoic acid.

Authors:  Y Inoue; M Fujisawa; M Shoji; S Hashizume; Y Katakura; S Shirahata
Journal:  Cytotechnology       Date:  2000-07       Impact factor: 2.058

View more
  3 in total

1.  Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity.

Authors:  Yoshinobu Konno; Yuki Kobayashi; Ken Takahashi; Eiji Takahashi; Shinji Sakae; Masako Wakitani; Kazuya Yamano; Toshiyuki Suzawa; Keiichi Yano; Toshio Ohta; Masamichi Koike; Kaori Wakamatsu; Shinji Hosoi
Journal:  Cytotechnology       Date:  2011-08-27       Impact factor: 2.058

2.  Advantages of AlaGln as an additive to cell culture medium: use with anti-CD20 chimeric antibody-producing POTELLIGENT™ CHO cell lines.

Authors:  Yasufumi Imamoto; Hisaya Tanaka; Ken Takahashi; Yoshinobu Konno; Toshiyuki Suzawa
Journal:  Cytotechnology       Date:  2012-06-14       Impact factor: 2.058

3.  A Pilot Study of the Photoprotective Effects of Strawberry-Based Cosmetic Formulations on Human Dermal Fibroblasts.

Authors:  Massimiliano Gasparrini; Tamara Yuliett Forbes-Hernandez; Sadia Afrin; José Miguel Alvarez-Suarez; Ana M Gonzàlez-Paramàs; Celestino Santos-Buelga; Stefano Bompadre; José Luis Quiles; Bruno Mezzetti; Francesca Giampieri
Journal:  Int J Mol Sci       Date:  2015-08-04       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.